Identification of plasma interleukins as biomarkers for DEFLAZACORT (cas 13649-88-2) and omega-3 based Duchenne muscular dystrophy therapy
-
Add time:09/10/2019 Source:sciencedirect.com
Duchenne muscular dystrophy (DMD) is a progressive and fatal disease, characterized by the absence of dystrophin, muscle degeneration and cardiorespiratory failure. Creatine kinase is the classic marker to screen for DMD. However, other markers are needed to follow disease progression and to evaluate the response to therapy over longer periods. In the present study, we aim to identify interleukins in the plasma of the mdx mice model of DMD that could serve as biomarkers to monitor dystrophy progression, at distinct stages of the disease (1, 3 and 8 months of age). We used DEFLAZACORT (cas 13649-88-2) and omega-3 therapies to validate the biomarkers studied. Plasma levels of TNF-α and TGF-β were increased in mdx mice in relation to control, at all times studied. Differences in IFN-γ and IL-10 contents, comparing mdx x CTRL, were detected only at the early stage (1 month). IL-6 decreased at 3 and 8 months and IL-13 increased at 8 months in the mdx compared to control. Deflazacort and omega-3 reduced the plasma levels of the pro-inflammatory (TNF-α, INF-γ, IL-6) and pro-fibrotic (IL-13 and TGF-β) interleukins and increased the plasma levels of IL-10. It is suggested that TNF-α and TGF-β in plasma would be the best markers to follow disease progression. IL-6, INF-γ and IL-10 would be suitable markers to the earlier stages of dystrophy and IL-13 a suitable marker to the later stages of dystrophy.
We also recommend Trading Suppliers and Manufacturers of DEFLAZACORT (cas 13649-88-2). Pls Click Website Link as below: cas 13649-88-2 suppliers
Prev:Original ArticleDEFLAZACORT (cas 13649-88-2) alleviate pro-inflammatory cytokines expression, oxidative stress and histopathological alterations in collagen induced arthritis in Wistar rats
Next:A comparative study of hydrocortisone versus DEFLAZACORT (cas 13649-88-2) in drug-resistant epilepsy of childhood) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Case reportTwo siblings with limb-girdle muscular dystrophy type 2E responsive to DEFLAZACORT (cas 13649-88-2)09/26/2019
- Case ReportToxic epidermal necrolysis associated with DEFLAZACORT (cas 13649-88-2) therapy with nephrotic syndrome09/25/2019
- A comparative study of hydrocortisone versus DEFLAZACORT (cas 13649-88-2) in drug-resistant epilepsy of childhood09/24/2019
- Original ArticleDEFLAZACORT (cas 13649-88-2) alleviate pro-inflammatory cytokines expression, oxidative stress and histopathological alterations in collagen induced arthritis in Wistar rats09/09/2019
- Short communicationIsolation and structural characterization of novel photolytic degradation impurities of DEFLAZACORT (cas 13649-88-2) using Q-TOF, 2D-NMR and FTIR09/08/2019
- DEFLAZACORT (cas 13649-88-2)09/07/2019
- Determination of the solubility, dissolution enthalpy and entropy of DEFLAZACORT (cas 13649-88-2) in different solvents09/06/2019
- Clinical ObservationsThe Impact of DEFLAZACORT (cas 13649-88-2) on Puberty in Duchenne Muscular Dystrophy09/05/2019